- Home
- CATO vs ADVM Comparison
CATO vs ADVM Comparison
Compare CATO & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATO
- ADVM
- Stock Information
- Founded
- CATO 1946
- ADVM 2006
- Country
- CATO United States
- ADVM United States
- Employees
- CATO N/A
- ADVM N/A
- Industry
- CATO Clothing/Shoe/Accessory Stores
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CATO Consumer Discretionary
- ADVM Health Care
- Exchange
- CATO Nasdaq
- ADVM Nasdaq
- Market Cap
- CATO 59.2M
- ADVM 47.4M
- IPO Year
- CATO N/A
- ADVM 2014
- Fundamental
- Price
- CATO $2.81
- ADVM $2.74
- Analyst Decision
- CATO
- ADVM Strong Buy
- Analyst Count
- CATO 0
- ADVM 5
- Target Price
- CATO N/A
- ADVM $23.80
- AVG Volume (30 Days)
- CATO 34.4K
- ADVM 297.2K
- Earning Date
- CATO 08-21-2025
- ADVM 08-11-2025
- Dividend Yield
- CATO 6.05%
- ADVM N/A
- EPS Growth
- CATO N/A
- ADVM N/A
- EPS
- CATO N/A
- ADVM N/A
- Revenue
- CATO $642,949,000.00
- ADVM $1,000,000.00
- Revenue This Year
- CATO N/A
- ADVM N/A
- Revenue Next Year
- CATO N/A
- ADVM $18.82
- P/E Ratio
- CATO N/A
- ADVM N/A
- Revenue Growth
- CATO N/A
- ADVM N/A
- 52 Week Low
- CATO $2.19
- ADVM $1.78
- 52 Week High
- CATO $6.70
- ADVM $10.14
- Technical
- Relative Strength Index (RSI)
- CATO 46.89
- ADVM 59.62
- Support Level
- CATO $2.79
- ADVM $2.50
- Resistance Level
- CATO $3.07
- ADVM $2.75
- Average True Range (ATR)
- CATO 0.18
- ADVM 0.20
- MACD
- CATO -0.02
- ADVM 0.06
- Stochastic Oscillator
- CATO 16.67
- ADVM 82.50
About CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.